TABLE 2.

Overall median CD4 among HIV-positive and HIV-negative individuals (excluding Uganda), reported by age group from aggregate data in 11 population-based HIV impact assessment (PHIA) countries as well as by detectable antiretrovirals (ARV) and undetectable ARVs^a

Ageb (yrs)	HIV negativec (n = 7,329)		HIV positived
	n	Median (Q1, Q3)	Total (n = 22,892)		Detectable ARVs (n = 15,439)		Non-detectable ARVs (n = 7,453)
			n	Median (Q1, Q3)	n	Median (Q1, Q3)	n	Median (Q1, Q3)	P valuee
0 to 5	983	1,470 (1,104, 1,938)	163	995 (665, 1,418)	83	1,071 (689, 1,513)	80	857 (640, 1,271)	0.0229
6 to 14	1,140	999 (797, 1,267)	476	772.5 (527, 1,108)	323	884 (587, 1,192)	153	596 (413, 824)	<0.0001
15 to 29	2,659	830 (662, 1,025)	4,919	508 (344, 706)	2,538	580 (406, 771)	2,381	441 (295, 618)	<0.0001
30 to 44	1,455	807 (656, 1,006)	10,737	461 (299, 642)	7,394	505 (347, 678)	3,343	359 (223, 529)	<0.0001
45+	1,092	776.5 (596, 988)	6,597	451 (295, 634)	5,101	478 (326, 654)	1,496	352 (211, 531.5)	<0.0001
0 to 14	2,123	1,171 (885, 1,580)	639	823 (561, 1,171)	406	914 (615, 1,244)	233	675 (465, 951)	<0.0001
15+	5,206	811 (647, 1,013)	22,253	468 (307, 654)	15,033	508 (349, 686)	7,220	385.5 (242, 563.5)	<0.0001

^aAll of the CD4 data are unweighted. Abbreviations: Q1, first quartile; Q3, third quartile.

^bThe eligible age-range to participate in the PHIA study was 0 to 64 years in Cameroon, Côte d’Ivoire, Ethiopia, Malawi, Namibia, Zimbabwe and Uganda; 0 to 59 years in Zambia and Lesotho; and 15+ years in Eswatini and Tanzania.

^cExcludes Uganda. CD4 cell count measurements for participants who tested HIV-negative were not part of the protocol.

^dThe HIV-positive participants with missing ARV measurements (n = 193) were excluded from analysis.

^eThe Wilcoxon P values are among the HIV-positive groups, comparing detectable and undetectable ARVs.